Skip to main content

Table 1 Subject demographics and lung function

From: Altered deposition of inhaled nanoparticles in subjects with chronic obstructive pulmonary disease

 

Healthy Never-Smokers

(n = 17)

Asymptomatic Smokers

(n = 15)

COPD

(n = 16)

Male/Female

9/8

6/9

7/9

Age [y]

64 ± 6

62 ± 3

67 ± 7

Weight [kg]

76 ± 14

76 ± 12

72 ± 13

Height [cm]

173 ± 9

169 ± 9

170 ± 9

FEV1%pred

110 ± 15

109 ± 13

61 ± 23***

VC %pred

109 ± 20

112 ± 13

107 ± 18

FEV1/VC %pred

78.6 ± 4.0

78.4 ± 5.6

44.9 ± 14.2***

DL,CO %pred

92.0 ± 10

88.2 ± 13

60.2 ± 22***†

GOLD-stage (1/2/3/4)

  

3/7/5/1

  1. † Data for DL,CO for one subject in the COPD group is missing
  2. ***Significance < 0.001 level
  3. Descriptive demographic data (average ± 1 standard deviation) for the subjects, lung function tests performed post bronchodilation, 1.5 mg terbutaline (Bricanyl Turbuhaler, Astra Zeneca, Mölndal, Sweden)
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us